About

June Lee has served as an independent director of Abivax since July 2023. She has been a venture partner at 5AM Venture Management since July 2022 and was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. She previously served as Executive Vice President and Chief Development Officer of MyoKardia and, before that, on the faculty of the University of California, San Francisco, directing the Catalyst accelerator program, and as a disease area lead in early clinical development at Genentech. She currently serves on the boards of Tenaya Therapeutics, Eledon Pharmaceuticals and GenEdit. She holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis. She chairs the Remuneration Committee and the Science and Clinical Committee.

Roles

Abivax S.A.
Independent Director · Current role
July 2023–present
5AM Venture Management, LLC
Venture Partner
2022 - present
Esker Therapeutics
Founder and Chief Executive Officer
- 2021
MyoKardia, Inc.
EVP & Chief Development Officer / COO
2017 - 2020
University of California, San Francisco (UCSF)
Faculty; Director, Catalyst program
2011 - 2017
Genentech, Inc.
Disease area lead, early clinical development / Medical Director
2004 - 2011

External Roles

Tenaya Therapeutics Inc.
Director
present
Eledon Pharmaceuticals Inc.
Director
present
GenEdit
Director
present

Director Compensation

FY 2025
Gross fees earned
€127,500
ComponentDirector attendance fees / remuneration earned in FY2025 (paid in euros)
Total
€127,500

Also at Abivax S.A.

Related

See how VectorShift works for your firm

Request Demo